SCHEMBL6441776

SCHEMBL6441776

ON=Cc1ccc(Cl)c(Cl)c1OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.54
HPGD P15428 2/20 0.54
GAA P10253 1/20 0.54
RAB9A P51151 5/20 0.52
NPC1 O15118 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
NFKB1 P19838 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
CYP1A2 P05177 3/20 0.51
CYP3A4 P08684 3/20 0.51
CYP2C19 P33261 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
CYP2D6 P10635 2/20 0.51
CYP2C9 P11712 1/20 0.51
LMNA P02545 4/20 0.43
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6911539 0.81 CCNB2 (0.42) MAPTHPGDRAB9ANPC1SMN1; SMN2
SCHEMBL10848977 0.75 LMNA (0.46) MAPTHPGDGAAMEN1KMT2A
SCHEMBL6443594 0.73 KDM4E (0.43) MAPTHPGDGAARAB9ANPC1
SCHEMBL10849569 0.73 MRGPRX4 (0.49) MAPTHPGDGAARAB9ANPC1
SCHEMBL28863987 0.72 RAB9A (0.77) MAPTHPGDGAARAB9ANPC1
SCHEMBL4515720 0.72 MAPT (0.52) MAPTHPGDGAARAB9ANPC1
SCHEMBL4515723 0.72 MAPT (0.52) MAPTHPGDGAARAB9ANPC1
SCHEMBL5761016 0.70 MAPT (0.49) MAPTHPGDGAARAB9ANPC1
SCHEMBL7908854 0.70 RAB9A (0.56) MAPTHPGDGAARAB9ANPC1
SCHEMBL7908857 0.70 RAB9A (0.56) MAPTHPGDGAARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004039409-A2 COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF SWITCH BIOTECH AG (DE) 2004-05-13 WO claimed
EP-1345618-B1 CHLORZOXAZONE FOR THE TREATMENT OF PSORIASIS SWITCH BIOTECH AG (DE) 2005-03-23 EP disclosed
US-20040248099-A1 Use of intermediate -conductance potassium channels and modulators for diagnosing and treating diseases having disturbed keratinocyte activity SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) 2004-12-09 US disclosed
WO-2004039409-A2 COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF SWITCH BIOTECH AG (DE) 2004-05-13 WO disclosed
EP-1345618-A2 USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY Switch Biotech Aktiengesellschaft (DE) 2003-09-24 EP disclosed
WO-2002053171-A2 USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) 2002-07-11 WO disclosed